Endovascular treatment in patients with cervical or intracranial isolated internal carotid artery occlusion: A systematic review and meta-analysis.

Neuroradiol JFeb 4, 2026 (epub)
Clinical ResearchNeurologyCardiologyOpen access

Mariana Letícia de Bastos Maximiano, Ocilio Ribeiro Gonçalves, Luciano Falcão et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis compared endovascular treatment (EVT) with best medical treatment (BMT) for adults with acute ischemic stroke due to isolated internal carotid artery occlusion, including cervical and intracranial occlusions. Five studies included 1531 patients. EVT was not associated with a statistically significant improvement in 90-day functional independence (mRS 0–2; OR 1.78; 95% CI 0.99-3.21), and adjusted analyses showed a smaller, also nonsignificant association (OR 1.22; 95% CI 0.82-1.82). Mortality and symptomatic intracranial hemorrhage also did not differ significantly between treatment groups.

Key findings

  • Across five studies and 1531 patients, EVT did not significantly improve 90-day functional independence versus BMT (OR 1.78; 95% CI 0.99-3.21; I 2 = 71%).
  • Adjusted analyses attenuated the association with functional independence (OR 1.22; 95% CI 0.82-1.82).
  • There were no significant group differences in 90-day mortality (OR 0.84; 95% CI 0.64-1.09) or symptomatic intracranial hemorrhage (OR 1.48; 95% CI 0.72-3.07).
  • Subgroup analyses by cervical versus intracranial occlusion showed similar neutral results, although a benefit for intracranial occlusions could not be excluded.

Why it matters

Patients with isolated internal carotid artery occlusion were largely excluded from pivotal thrombectomy trials, leaving uncertainty about the role of EVT. This synthesis finds no demonstrated superiority over medical treatment for functional outcome, mortality, or symptomatic hemorrhage. It helps define the current evidence gap while underscoring that treatment effects, particularly by occlusion site, remain uncertain.

What to keep in mind

The evidence came from five studies, and EVT patients were younger and had more severe strokes. The pooled functional-independence analysis had substantial heterogeneity (I 2 = 71%); the findings are observational and hypothesis-generating.

Source

Published in Neuroradiol J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.